Metastatic Hormone-sensitive Prostate Cancer Clinical Trials
3 recruiting trials for Metastatic Hormone-sensitive Prostate Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Metastatic Hormone-sensitive Prostate Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2: 1.
Research is led by Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1), Astellas Pharma Global Development, Inc. (1), Janssen Cilag S.A.S. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Apalutamide (Erleada™) 60 mg or 240 mg tablets (drug, 1 trial), followed by Docetaxel, ASP5541.
Track Metastatic Hormone-sensitive Prostate Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus...
This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free...
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in...
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Metastatic Hormone-sensitive Prostate Cancer, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Metastatic Hormone-sensitive Prostate Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Metastatic Hormone-sensitive Prostate Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.